NCT06429176View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

December 31, 2025

Conditions
Cystic Fibrosis
Interventions
DRUG

SPL84

SPL84 solution for nebulization

OTHER

Placebo

Placebo solution for nebulization

Trial Locations (2)

43205

RECRUITING

Nationwide Children'S Hospital, Columbus

02115

RECRUITING

Boston Children'S Hospital, Boston

All Listed Sponsors
lead

SpliSense Ltd.

INDUSTRY